5-Fluorouracil as adjuvant chemotherapy for large bowel cancer. Is it appropriate for routine community use?
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to S K Carter.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The question of whether estrogen receptor assay predicts for chemotherapy response and, if so, how, is currently controversial. Two papers have recently appeared with widely differing results. Both papers use retrospective analysis and are so heterogeneous as regards assay criteria for positivity, prognostic variable and drugs used that they cannot in truth be meaningfully compared. Resolution of the question will probably have to await prospectively designed trials.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Potential anti-cancer agents have classically undergone clinical assessment in Phase I, II and III trials. This paper examines the role of these trials and pre-clinical studies in the light of improving cancer chemotherapy. Many patients must now be treated with standard therapy before investigational drugs can be ethically used. The introduction of combined modality trials will require a very prolonged follow-up to demonstrate improved survival and recognize late onset of chronic toxicity.